Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RXi Pharmaceuticals, a biopharmaceutical company developing proprietary therapeutics based on RNA interference, has appointed Anastasia Khvorova as its new chief scientific officer.
Subscribe to our email newsletter
Dr Khvorova has previously served as chief scientific officer at Dharmacon, a developer and supplier of RNAi compounds. Prior to Dharmacon, Dr Khvorova served as research scientist with Amgen, where, among other areas, she worked on the development of RNAi technology.
Tod Woolf, president and CEO of RXi Pharmaceuticals, said: “Among her many accomplishments, Dr Khvorova’s group at Dharmacon designed and manufactured RNAi compounds targeting virtually all of the known human genes.
“Moreover, Dr Khvorova is one of the most widely cited authors of research articles in the field of RNAi, which serves as a testament to the impact her work has had in the field. Through her research, Dr Khvorova also developed ‘self-delivering’ RNAi compounds in her previous role as chief scientific officer at Dharmacon.”